Mucosal Melanoma

P4, N=90, Recruiting, NYU Langone Health | Not yet recruiting --> Recruiting

NRAS was the most frequent mutation, followed by ARID1A, CDK4, CDKN2A, JAK2 and MYC, without a significant association with survival. These results emphasise the prognostic value of mitotic index and surgical completeness, while confirming the marked molecular heterogeneity of mucosal melanoma and the lack of a single dominant actionable alteration.

P2, N=70, Not yet recruiting, Shanghai Zhongshan Hospital

P2, N=20, Not yet recruiting, M.D. Anderson Cancer Center

P2, N=101, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Sep 2026 | Trial primary completion date: Jun 2026 --> Sep 2026

P1, N=75, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027

P1, N=17, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed

Inhibition of HER2/3 by pan-HER inhibitors blocks cell state plasticity and overcomes chemoresistance in primary MM cell lines and patient-derived xenograft (PDX) models. These findings provide insights into how the tissue of origin determines cancer aggressiveness, highlight the role of mucosal inflammation in driving melanoma stemness and chemoresistance, and advance the identification of effective treatment options currently lacking for patients with MM.

P4, N=90, Not yet recruiting, NYU Langone Health

P=N/A, N=68, Completed, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Interestingly, some of these patients may derive meaningful benefit from cytotoxic chemotherapy. We present the report of a case of a 63-year-old lady with BRAF wild type, locally advanced mucosal melanoma who demonstrated disease progression on combination immunotherapy with Ipilimumab and nivolumab. She subsequently achieved an exceptional and durable radiological and clinical response to chemotherapy with cisplatin and dacarbazine. This case highlights that, despite advances in personalized medicine and immunotherapy, conventional chemotherapy may still represent a valuable therapeutic option in selected patients, particularly in the refractory setting.

P1, N=210, Active, not recruiting, iOnctura | Trial completion date: Mar 2025 --> Mar 2027